hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides a
hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides a
hVIVO plc (AIM & Euronext: HVO), a fast growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that
£2.5m Contract for Omicron characterisation study
In its latest investment research note, Stifel highlights hVIVO PLC’s strong position in the global healthcare market, notably in conducting human challenge clinical trials (HCTs) for infectious and respiratory diseases.
A record year across all financial and operational metrics On track to deliver future growth targets Initiating annual dividend policy
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a
Open Orphan distribution in specie shares and in particular some people had been concerned that they were unable to trade them.
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the
mutex to present positive Phase I clinical study results for AGS-v PLUS mosquito vaccine candidate AGS-v PLUS mosquito vaccine candidate shows favourable safety, tolerability, and immunogenicity results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
£1.5m Contract renewal for Venn Life Sciences with a major global pharmaceutical client
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the appointment